ATE252585T1 - Bicyclischer lactaminhibitor des interleukin-1- beta-konvertierenden enzyms - Google Patents

Bicyclischer lactaminhibitor des interleukin-1- beta-konvertierenden enzyms

Info

Publication number
ATE252585T1
ATE252585T1 AT95923013T AT95923013T ATE252585T1 AT E252585 T1 ATE252585 T1 AT E252585T1 AT 95923013 T AT95923013 T AT 95923013T AT 95923013 T AT95923013 T AT 95923013T AT E252585 T1 ATE252585 T1 AT E252585T1
Authority
AT
Austria
Prior art keywords
beta
interleukin
lactamine
hibitor
bicyclic
Prior art date
Application number
AT95923013T
Other languages
English (en)
Inventor
Roland E Dolle
Prasad V Chaturvedula
Ross Tina Morgan
Stanley J Schmidt
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE252585T1 publication Critical patent/ATE252585T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95923013T 1994-06-08 1995-06-08 Bicyclischer lactaminhibitor des interleukin-1- beta-konvertierenden enzyms ATE252585T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/255,276 US5552400A (en) 1994-06-08 1994-06-08 Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
PCT/US1995/007314 WO1995033751A1 (en) 1994-06-08 1995-06-08 Bicycling lactam inhibitor of interleukin-1-beta converting enzyme

Publications (1)

Publication Number Publication Date
ATE252585T1 true ATE252585T1 (de) 2003-11-15

Family

ID=22967606

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03018280T ATE464314T1 (de) 1994-06-08 1995-06-08 Bizyklischer lactaminhibitor des interleukin-1- beta-konvertierenden enzyms
AT95923013T ATE252585T1 (de) 1994-06-08 1995-06-08 Bicyclischer lactaminhibitor des interleukin-1- beta-konvertierenden enzyms

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03018280T ATE464314T1 (de) 1994-06-08 1995-06-08 Bizyklischer lactaminhibitor des interleukin-1- beta-konvertierenden enzyms

Country Status (12)

Country Link
US (2) US5552400A (de)
EP (2) EP0764167B1 (de)
JP (1) JP4173536B2 (de)
AT (2) ATE464314T1 (de)
AU (1) AU705882B2 (de)
CA (1) CA2192360C (de)
DE (2) DE69536064D1 (de)
DK (1) DK0764167T3 (de)
ES (2) ES2210294T3 (de)
HU (1) HU226979B1 (de)
PT (1) PT764167E (de)
WO (1) WO1995033751A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100856767B1 (ko) * 1966-11-26 2009-06-16 버텍스 파마슈티칼스 인코포레이티드 인터류킨-1 베타 전환효소의 억제제
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6245764B1 (en) * 1995-03-24 2001-06-12 Molecumetics Ltd. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US6699869B1 (en) 1995-03-24 2004-03-02 Myriad Genetics Inc. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US6020331A (en) * 1995-03-24 2000-02-01 Molecumetics, Ltd. β-sheet mimetics and use thereof as protease inhibitors
US6162828A (en) * 1995-03-31 2000-12-19 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
AU756253B2 (en) * 1995-12-20 2003-01-09 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1beta converting enzyme
CA2251292A1 (en) * 1996-04-12 1997-10-23 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ace inhibitors and/or nep inhibitors
US6117896A (en) * 1997-02-10 2000-09-12 Molecumetics Ltd. Methods for regulating transcription factors
NZ334906A (en) 1996-10-11 2000-09-29 Basf Ag A sulphonamido pentanoic acid derivative useful as an interleukin-1-beta converting enzyme inhibitor
US5919790A (en) * 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
CA2268103A1 (en) * 1996-10-11 1998-04-23 Warner-Lambert Company Sulfonamide substituted aspartic acid interleukin-1.beta. converting enzyme inhibitors
JP4499917B2 (ja) * 1998-03-09 2010-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−１β変換酵素のインヒビターとしての１，２−ジアゼパン誘導体
KR100898094B1 (ko) 1998-03-19 2009-05-18 버텍스 파마슈티칼스 인코포레이티드 카스파제의 억제제
FR2777279B1 (fr) * 1998-04-08 2004-08-13 Hoechst Marion Roussel Inc Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide
CA2327185A1 (en) * 1998-04-08 1999-10-14 Abbott Laboratories Pyrazole inhibitors of cytokine production
AU2003200034B2 (en) * 1998-04-27 2006-07-20 Aventis Pharma S.A. New derivatives of octahydro-6, 10-dioxo-6H-pyridazino [1,2-A][1,2]diazepine-1-carboxylic acid, their preparation process and their use in the preparation of therapeutically active compounds
FR2777889B1 (fr) 1998-04-27 2004-07-09 Hoechst Marion Roussel Inc Nouveaux derives de l'acide octahydro-6,10-dioxo-6h- pyridazino[1,2-a][1,2]diazepine-1-carboxylique, leur procede de preparation et leur application a la preparation de composes therapeutiquement actifs
FR2802927B1 (fr) * 1999-12-28 2002-03-01 Hoechst Marion Roussel Inc Nouveaux derives de diazepine carboxamide, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et leur nouvelle utilisation
EP2241328A1 (de) * 2000-05-12 2010-10-20 Immunex Corporation Interleukin-1 Inhibitoren zur Behandlung von Erkrankungen
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
JP2003535865A (ja) 2000-06-07 2003-12-02 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼインヒビターおよびその使用
US7410956B2 (en) * 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
JP2005526722A (ja) 2002-02-14 2005-09-08 ミリアド・ジェネティックス・インコーポレイテッド β−シートミメティックならびにそれに関連する組成物および方法
AU2003275304A1 (en) * 2002-10-01 2004-04-23 Musc Oundation For Research Development Use of caspase inhibitors as therapeutic agent against radiation-induced injury
MXPA06013256A (es) * 2004-05-15 2007-02-08 Vertex Pharma Tratamiento de crisis convulsivas utilizando inhibidores ice.
CA2567080A1 (en) * 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
US9116157B2 (en) 2010-11-05 2015-08-25 Brandeis University Ice-cleaved alpha-synuclein as a biomarker
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
WO2013053657A1 (en) * 2011-10-10 2013-04-18 F. Hoffmann-La Roche Ag Antiviral compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0025941B1 (de) * 1979-09-19 1983-05-04 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Pyridazopyridazinderivate, Verfahren zu deren Herstellung und Arzneimittel enthaltend solche Pyridazopyridazinderivate
EP0042100A1 (de) * 1980-06-13 1981-12-23 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Pyrazolopyridazin-Derivate, Zwischenprodukte und Verfahren zu deren Herstellung, sowie diese enthaltende Arzneimittel
ZA833214B (en) * 1982-05-12 1983-12-28 Hoffmann La Roche Bicyclic compounds
JP2543503B2 (ja) * 1986-07-01 1996-10-16 綜研化学株式会社 分岐構造を有する共重合体を分散安定剤として用いた乳化重合法
EP0519748B1 (de) * 1991-06-21 1998-09-02 Merck & Co. Inc. Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
GB9123326D0 (en) * 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
DE69320176T2 (de) * 1992-02-21 1999-04-08 Merck & Co., Inc., Rahway, N.J. Peptidylderivate und inhibitoren des interleukin-1-g(b)-konvertierenden enzyms
AU669364B2 (en) * 1992-05-15 1996-06-06 Merrell Pharmaceuticals Inc. Novel mercaptoacetylamido pyridazo(1,2)pyridazine, pyrazolo(1,2)pyridazine, pyridazo(1,2-a)(1,2)diazepine and pyrazolo(1,2-a)(1,2)diazepine derivatives useful as inhibitors of enkephalinase and ace
EP0618223A3 (de) * 1993-03-08 1996-06-12 Sandoz Ltd Peptide, die Freisetzung vom Interleukin 1-Bêta, nützlich als entzündungshemmende Wirkstoffe.

Also Published As

Publication number Publication date
HUT76334A (en) 1997-08-28
DK0764167T3 (da) 2004-02-09
ES2341949T3 (es) 2010-06-30
HK1064102A1 (en) 2005-01-21
EP1391461A1 (de) 2004-02-25
HK1012630A1 (en) 1999-08-06
US5552400A (en) 1996-09-03
EP0764167B1 (de) 2003-10-22
DE69536064D1 (de) 2010-05-27
DE69531990D1 (de) 2003-11-27
AU2769995A (en) 1996-01-04
DE69531990T2 (de) 2004-09-02
HU9603376D0 (en) 1997-01-28
AU705882B2 (en) 1999-06-03
HU226979B1 (en) 2010-04-28
MX9606192A (es) 1998-06-30
CA2192360A1 (en) 1995-12-14
CA2192360C (en) 2007-08-07
ATE464314T1 (de) 2010-04-15
WO1995033751A1 (en) 1995-12-14
EP1391461B1 (de) 2010-04-14
JP4173536B2 (ja) 2008-10-29
EP0764167A4 (de) 1997-09-17
ES2210294T3 (es) 2004-07-01
EP0764167A1 (de) 1997-03-26
PT764167E (pt) 2004-03-31
JPH10501244A (ja) 1998-02-03
US5639745A (en) 1997-06-17

Similar Documents

Publication Publication Date Title
ATE252585T1 (de) Bicyclischer lactaminhibitor des interleukin-1- beta-konvertierenden enzyms
FI942625A0 (fi) Peptidisiä fosfinyylioksimetyyliketoneja interleukiini-1beta-muuttuvan entsyymin inhibiittoreina
MX9206008A (es) Inhibidores de enzima proteolitica, derivados de sacarina 2-substituida.
DE69214397D1 (de) 2-Substituierte Indane-2-Carboxyalkyl-Verbindungen mit Enkephalinase und ACE-Hemmwirkung
DK0752987T3 (da) Pyrimidinylderivater som interleukininhibitorer
FI925787A0 (fi) Proteolytiska enzymers sackarinderivatinhibitorer
IL119461A (en) 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
GR3026222T3 (en) Novel mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
DE69220744D1 (de) 2-Substituierte Indan-2-Mercaptoacetylamid-Verbindungen mit Enkephalinase und ACE-Hemmwirkung
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
EP0471756A4 (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof
IT1195814B (it) Composizione e procedimento per la conservazione di vegetali particolarmente fiori e piante
DK0765320T3 (da) Benzimidazolonderivater med central dopaminerg aktivitet
FI925946A7 (fi) Uusia 2-sakkarinyylimetyyliaryyli- ja -aryylioksiasetaatteja, jotka ovat käyttökelpoisia proteolyyttisten entsyymien inhibiittoreina, niitä sisältäviä koostumuksia ja niiden käyttö
FI925947A7 (fi) Uusia heterosyklisiä 2-sakkarinyylimetyylikarboksylaatteja, jotka ovatkäyttökelpoisia proteolyyttisten entsyymien inhibiittoreina, niitä sisältäviä koostumuksia ja niiden käyttö
FI970469A0 (fi) Bentsimidatsolijohdannaisia, joilla on dopaminerginen aktiivisuus
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
IT1216104B (it) Peptidi ad attivita' farmaceutica.
NZ208996A (en) 5-substituted(1,2,4 triazpyrimidin-2-amine derivatives and pharmaceutical compositions
NO970498L (no) Benzimidazolderivater med dopaminergisk aktivitet
SU1455633A1 (ru) О,о-диизопропил-о-[1, 1-диметил-2-пропилтио-2-(о-о-диизопропилфосфорил)- имино]-этилфосфат, обладающий бактерицидной активностью
GR3032850T3 (en) Use of hydrolytic enzyme for reducing or preventing side effects of bleomycine.
BE900618A (fr) Derives de 4,5,6,7-tetrahydrobenzimidazole.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0764167

Country of ref document: EP

REN Ceased due to non-payment of the annual fee